-
FDA exploring how to expand eligible Rx-to-OTC switches by utilizing pharmacy
SILVER SPRING, Md. — The Food and Drug Administration on Tuesday announced it will hold a public hearing on March 22 and 23 to discuss how technology can expand which drug products can be switched from prescription to over-the-counter status.
-
Par completes acquisition of Edict
WOODCLIFF LAKE, N.J. — Generic drug maker Par Pharmaceutical has completed its acquisition of an Indian drug company, Par said.
Par announced that it had completed its $20.5 million acquisition of Chennai, India-based Edict Pharmaceuticals.
Edict specializes in oral solid drugs and currently has 11 regulatory approval applications under review at the Food and Drug Administration.
Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.